Linked Life Data

8428104

Source:http://linkedlifedata.com/resource/pubmed/id/8428104

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1993-3-9
pubmed:abstractText
A new hepatobiliary contrast agent for magnetic resonance (MR) imaging, gadolinium-ethoxybenzyl (EOB)-diethylemetriaminepentaacetic acid (DTPA), was compared with Gd-DTPA to define the potential for improving tumor-liver contrast in a rodent liver adenocarcinoma model. With a T1-weighted spin-echo sequence, the contrast-to-noise ratio (C/N) for tumor before contrast agent administration was 5 (arbitrary units), the tumor appearing slightly hypo-intense with respect to liver parenchyma. After Gd-DTPA injection (0.1 mmol/kg), tumor enhanced more strongly than liver, resulting in an equalization of tumor and liver signal intensities and a decline in C/N to zero at 3 minutes after injection. After Gd-EOB-DTPA injection (0.1 mmol/kg), liver enhanced more strongly than tumor. Five minutes after injection, C/N increased from 5 to 25 and remained above 17 for 50 minutes. The data indicate that Gd-EOB-DTPA yields higher and more prolonged tumor-liver contrast than Gd-DTPA on T1-weighted spin-echo images. The high liver-tumor contrast after Gd-EOB-DTPA administration should prove clinically advantageous for MR imaging detection of focal hepatic masses.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1053-1807
pubmed:author
pubmed:issnType
Print
pubmed:volume
3
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
71-7
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed:articleTitle
Comparison of Gd-EOB-DTPA and Gd-DTPA for contrast-enhanced MR imaging of liver tumors.
pubmed:affiliation
Department of Radiology, University of California, San Francisco 94143-0628.
pubmed:publicationType
Journal Article, Comparative Study, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't